Antiphospholipid syndrome: antibodies to Domain 1 of β2‐glycoprotein 1 correctly classify patients at risk. (5th March 2015)

• Record Type: Journal Article
• Authors: Pengo, V.; Ruffatti, A.; Tonello, M.; Cuffaro, S.; Banzato, A.; Bison, E.; Denas, G.; Padayattil Jose, S.
• Is Part Of: Journal of thrombosis and haemostasis. Volume 13:Number 5(2015:May)
• Page Start: 782
• Page End: 787
• Publication Date: 2015-03-05
• Subjects: Thrombosis -- Periodicals; Hemostasis -- Periodicals; Blood coagulation disorders -- Periodicals; 616.1
• DOI: 10.1111/jth.12865
• Languages: English
• ISSNs: 1538-7933

Abstract

<abstract abstract-type="main" id="jth12865-abs-0001"> <title>Summary</title> <sec id="jth12865-sec-0001" sec-type="section"> <title>Background</title> <p>Determination of lupus anticoagulant (LA), anticardiolipin (aCL) and β2‐Glycoprotein 1 (aβ2GP1) antibodies is mandatory to classify patients with antiphospholipid syndrome (APS) into risk categories.</p> </sec> <sec id="jth12865-sec-0002" sec-type="section"> <title>Objectives</title> <p>To measure relevant antibodies, considered to be those of the IgG isotype directed towards β2GP1 and particularly those directed to Domain 1 (Dm1) of the molecule.</p> </sec> <sec id="jth12865-sec-0003" sec-type="section"> <title>Patients/methods</title> <p>In this cross‐sectional study we measured IgG aβ2GP1‐Dm1 by a chemiluminescent immunoassay in a group of individuals initially positive for IgG aβ2GP1 and classified as triple (LAC+, IgG aCL+, IgG aβ2GP1+, <italic>n</italic> = 32), double (LAC–, IgG aCL+, IgG aβ2GP1+, <italic>n</italic> = 23) or single positive (LA‐, IgG aCL‐, IgG aβ2GP1+, <italic>n</italic> = 10).</p> </sec> <sec id="jth12865-sec-0004" sec-type="section"> <title>Results and conclusion</title> <p>Geometric mean and standard deviation expressed as chemiluminescent units (CU) in triple, double and single positive groups were 273.0 ± 6.2, 18.2 ± 9.6 and 4.4 ± 2.2, respectively. The geometric mean obtained in 40 healthy subjects was 2.0 ± 2.0. Mean CU values were significantly different among groups and with respect to values found in 40 healthy subjects (<italic>P</italic> < 0.0001). Positive values of IgG aβ2GP1‐Dm1 (above 14.2 CU) were found in 45 individuals while 20 individuals (20/65 = 30.8%) positive for IgG aβ2GP1 were negative for IgG aβ2GPI‐Dm1. There was a significant association between positive IgG aβ2GP1‐Dm1 and thromboembolic events (<italic>P</italic> = 0.001). Positive and negative values of IgG aβ2GP1‐Dm1 were consistently confirmed after 12 weeks, with only three low positive values being negative after 12 weeks. In conclusion, IgG aβ2GP1‐Dm1 seems a robust and reproducible test that in association with the classic tests may be useful in clinical practice in identifying individuals at high risk of developing thromboembolic events.</p> </sec> </abstract>